Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
この品目はお気に入りに追加されました。
動物種
パネルタイプ
選択したキット
数量
カタログ番号
注文内容
Qty/Pk
価格
96-Well Plate
数量
カタログ番号
注文内容
Qty/Pk
価格
その他の試薬を追加 （MAPmatesとともに使用するにはバッファーおよび検出キットが必要です）
数量
カタログ番号
注文内容
Qty/Pk
価格
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option（チェックを入れると箱詰めから袋詰めに変更となりますのでご注意ください） Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
A cell-permeable macrocyle cyclotriazadisulfonamide derivative compound that inhibits HIV replication (IC50 = 300 nM to 3.3 µM) and entry into cells by blocking co-translational translocation of nascent CD4 across endoplasmic reticulum membranes. Its action appears to be highly selective in reducing the expression of human CD4 and it does not affect the level of any other cell surface marker studied. Does not affect CD4 mRNA levels in cells. Shown to be effective against HIV-1 subtypes A to H, AE, and O and human herpesvirus 7 (HHV-7; IC50, 300 nM to 1.5 µM) in T-cell lines and PBMCs. Also reported to block X4 HIV-1 NL4.3 and R5 SIVmac251 laboratory strains infection in human T cells. Can act synergistically with cellulose acetate phthalate (CAP) and other anti-HIV drugs to inhibit HIV-1 and SIV infections.
Catalogue Number
534337
Brand Family
Calbiochem®
Synonyms
1-Benzyl-7-methylene-5,9-ditosyl-5,9-diaza-azoniacyclododecan-1-ium chloride, CD4 Inhibitor, CADA
References
References
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246. Bell, T. W., et al. 2006. J. Med. Chem.49, 1291. Vermeire, K., et al. 2004. AIDS.18, 2115. Vermeire, K., et al. 2002. Virology.302, 342.
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246. Bell, T. W., et al. 2006. J. Med. Chem.49, 1291. Vermeire, K., et al. 2004. AIDS.18, 2115. Vermeire, K., et al. 2002. Virology.302, 342.
データシート
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
28-July-2017 JSW
Synonyms
1-Benzyl-7-methylene-5,9-ditosyl-5,9-diaza-azoniacyclododecan-1-ium chloride, CD4 Inhibitor, CADA
Description
A cell-permeable macrocyle cyclotriazadisulfonamide derivative compound that inhibits HIV replication (IC50 = 300 nM to 3.3 µM) and entry into cells by blocking co-translational translocation of nascent CD4 across endoplasmic reticulum membranes. Its action appears to be highly selective in reducing the expression of human CD4 and it does not affect the level of any other cell surface marker studied. Does not affect CD4 mRNA levels in cells. Shown to be effective against HIV-1 subtypes A to H, AE, and O and human herpesvirus 7 (HHV-7; IC50, 300 nM to 1.5 µM) in T-cell lines and PBMCs. Also reported to block X4 HIV-1 NL4.3 and R5 SIVmac251 laboratory strains infection in human T cells. Can act synergistically with cellulose acetate phthalate (CAP) and other anti-HIV drugs to inhibit HIV-1 and SIV infections.
Form
White solid
Intert gas (Yes/No)
Packaged under inert gas
Chemical formula
C₃₁H₃₉N₃O₄S₂·HCl
Purity
≥98% by HPLC
Solubility
DMSO (10 mg/ml). Insoluble in water.
Storage
Protect from light
-20°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Standard Handling
References
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246. Bell, T. W., et al. 2006. J. Med. Chem.49, 1291. Vermeire, K., et al. 2004. AIDS.18, 2115. Vermeire, K., et al. 2002. Virology.302, 342.
